Sep 12, 2023
by Suyeon Jang
Below is a summary of a recent news article announcing the unveiling of HyperLab:
HITS, an AI-driven drug discovery startup, will introduce its proprietary AI-powered drug discovery platform, HyperLab, at AIMECS 2023, held from October 25 to 28 at Conrad Hotel, Seoul.
Organized by the Asian Federation for Medicinal Chemistry (AFMC), AIMECS is a major international conference dedicated to the latest research and technological advancements in drug discovery.
HyperLab is a cloud-based SaaS platform that utilizes AI to predict drug-protein interactions and design novel drug structures. By lowering entry barriers in drug discovery research, it facilitates data sharing and seamless collaboration among researchers.
Jaechang Lim, Director at HITS, stated that AIMECS 2023 presents a valuable opportunity to showcase HITS' AI-driven drug discovery technology to a global audience.
📌 New Link
Below is a summary of a recent news article announcing the unveiling of HyperLab:
HITS, an AI-driven drug discovery startup, will introduce its proprietary AI-powered drug discovery platform, HyperLab, at AIMECS 2023, held from October 25 to 28 at Conrad Hotel, Seoul.
Organized by the Asian Federation for Medicinal Chemistry (AFMC), AIMECS is a major international conference dedicated to the latest research and technological advancements in drug discovery.
HyperLab is a cloud-based SaaS platform that utilizes AI to predict drug-protein interactions and design novel drug structures. By lowering entry barriers in drug discovery research, it facilitates data sharing and seamless collaboration among researchers.
Jaechang Lim, Director at HITS, stated that AIMECS 2023 presents a valuable opportunity to showcase HITS' AI-driven drug discovery technology to a global audience.
📌 New Link
Back to News